Supplements and Linagliptin.
Linagliptin, sold under the brand names Trajenta, Tradjenta, is a dipeptidyl peptidase-4 (DPP-4) inhibitor: it prolongs the action of incretin hormones.
Linagliptin is a DPP-4 inhibitor (dipeptidyl peptidase-4). Use is Type 2 diabetes as a second or third line oral agent. The class prolongs the action of endogenous incretin hormones (GLP-1 and GIP) by blocking their degradation, which raises insulin release in a way tied to glucose with low hypoglycaemia risk. UK prescribing centres on sitagliptin, linagliptin, alogliptin, and saxagliptin. The supplement surface is small because DPP-4 inhibitors have minimal CYP metabolism. Linagliptin is the cleanest in this respect. Clinical issues here are mostly glycaemic and additive. Berberine, cinnamon at extract doses, alpha lipoic acid, and chromium at high doses all carry small additive HbA1c effects. The stack rarely causes hypoglycaemia, but it is worth tracking in patients on tight glycaemic targets. Acute pancreatitis is a rare adverse effect flagged for the class.
We have not yet completed an explicit assessment of supplement interactions with Linagliptin in the Distil database. That is different from saying nothing exists. We surface this distinction deliberately: the Distil checker tells you when we have explicitly assessed a pair and when we have not, because both are useful information. If you take Linagliptin alongside a supplement, the checker below will surface anything already in our database, and the missing-item form at the bottom of the page routes uncatalogued pairs into our next curation pass.
What this list does not say. Pairs not flagged here are not implicitly safe. They are either not yet in our database, or fall outside our inclusion scope (food-supplement interactions only; for drug-drug interactions, the BNF is authoritative). Use the checker below to surface any supplement, and submit a missing item if you take something we have not catalogued.
No affiliates. No commission. We earn nothing on what you buy.
How the checker decides
Every result has a source
Each pair we have assessed is cited to a published study (PMID) or the British National Formulary, so you can read the source yourself.
Four kinds of answer
Severe, caution, no known interaction, and not yet assessed. A pair we have not assessed is never shown as clear.
- Severe
- Caution
- No known interaction
- Not yet assessed
Nothing in our data is not a clearance
When nothing in our data records a problem with a pair, the result says no known interaction at typical doses, which is not a clearance: your pharmacist or GP can check the pair against your full medical history.
A full supplement review, built around you, not a generic stack.
The free checker answers one interaction question at a time. A Distil report reviews the bigger picture: your goals, diet, medications, current supplements and any blood results you provide, then shows what appears worth keeping, changing, adding or leaving out.
- what your diet already covers, so you are not adding a capsule for something food is already handling
- which evidence-graded compounds are worth considering for your goals, and which were considered but left out
- what to keep, change or stop from what you already take, plus the order to introduce anything new
- how your medications and complete supplement stack fit together, with daily timing and a clear point for reassessment
The interaction check is one section of the full report. You also get the reasoning behind each recommendation and the evidence references used.
£49 until 30 June 2027 · £79 from 1 July 2027.
Something missing?
If a supplement or medication you take isn't in our autocomplete, tell us. What people flag joins the queue of what we add next.